#BEGIN_DRUGCARD DB06692

# AHFS_Codes:
20:28.16

# ATC_Codes:
B02AB01

# Absorption:
100% (IV)

# Biotransformation:
Aprotinin is slowly degraded by lysosomal enzymes.

# Brand_Mixtures:
Tisseel Kit Vh 1.0 (Aprotinin (Bovine) + Calcium Chloride + Factor Xiii + Fibrinogen (Human) + Plasmafibronectin (Cig) + Plasminogen + Thrombin (Human) + Total Protein)
Tisseel Kit Vh 2.0 (Aprotinin (Bovine) + Calcium Chloride + Factor Xiii + Fibrinogen (Human) + Plasmafibronectin (Cig) + Plasminogen + Thrombin (Human) + Total Protein)
Tisseel Kit Vh 5.0 (Aprotinin (Bovine) + Calcium Chloride + Factor Xiii + Fibrinogen (Human) + Plasmafibronectin (Cig) + Plasminogen + Thrombin (Human) + Total Protein)

# Brand_Names:
Trasylol

# CAS_Registry_Number:
9087-70-1

# ChEBI_ID:
Not Available

# Chemical_Formula:
C284H432N84O79S7

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
>Aprotinin (bovine pancreatic trypsin inhibitor)
RPDFCLEPPYTGPCKARIIRYFYNAKAGLCQTFVYGGCRAKRNNFKSAEDCMRTCGGA

# Creation_Date:
2009-02-12 09:44:30 -0700

# DPD_Drug_ID_Number:
2186845

# Description:
Aprotinin, also known as bovine pancreatic trypsin inhibitor, BPTI (Trasylol, Bayer) is a protein, that is used as medication administered by injection to reduce bleeding during complex surgery, such as heart and liver surgery. Its main effect is the slowing down of fibrinolysis, the process that leads to the breakdown of blood clots. The aim in its use is to decrease the need for blood transfusions during surgery, as well as end-organ damage due to hypotension (low blood pressure) as a result of marked blood loss. The drug was temporarily withdrawn worldwide in 2007 after studies suggested that its use increased the risk of complications or death; after this was confirmed by follow-up studies, Trasylol was entirely and permanently withdrawn in May 2008, except - at least for the time being - for very restricted research use. [Wikipedia]

# Dosage_Forms:
Solution	Intra-arterial

# Drug_Category:
Antifibrinolytic Agents

# Drug_Interactions:
Captopril	In study of nine patients with untreated hypertension, aprotinin infused intravenously in a dose of 2 million KIU over two hours blocked the acute hypotensive effect of 100mg of captopril.
Heparin	Aprotinin, in the presence of heparin, has been found to prolong the activated clotting time (ACT) as measured by a celite surface activation method. The kaolin activated clotting time appears to be much less affected.
Tenecteplase	Aprotonin may antagonize the effect of Tenecteplase. Monitor for decreased effects of Tenecteplase.
Urokinase	Aprotonin may antagonize the effect of Urokinase. Monitor for decreased effects of Urokinase.

# Drug_Reference:
15277296	Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth. 2004 Dec;93(6):842-58. Epub 2004 Jul 26.

# Drug_Type:
Approved
Biotech
Withdrawn

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Aprotinin

# HET_ID:
Not Available

# Half_Life:
Following this distribution phase, a plasma half-life of about 150 minutes is observed.  At later time points, (i.e., beyond 5 hours after dosing) there is a terminal elimination phase with a half-life of about 10 hours.

# InChI_Identifier:
Not Available

# InChI_Key:
Not Available

# Indication:
For prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion.

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
6693

# Mechanism_Of_Action:
Aprotinin inhibits several serine proteases, specifically trypsin, chymotrypsin and plasmin at a concentration of about 125,000 IU/ml, and kallikrein at 300,000 IU/ml. Its action on kallikrein leads to the inhibition of the formation of factor XIIa. As a result, both the intrinsic pathway of coagulation and fibrinolysis are inhibited. Its action on plasmin independently slows fibrinolysis.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
6511.4390

# Molecular_Weight_Mono:
Not Available

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Aprotinin Pathway	SMP00288

# PharmGKB_ID:
PA448472

# Pharmacology:
Aprotinin is a broad spectrum protease inhibitor which modulates the systemic inflammatory response (SIR) associated with cardiopulmonary bypass (CPB) surgery. SIR results in the interrelated activation of the hemostatic, fibrinolytic, cellular and humoral inflammatory systems. Aprotinin, through its inhibition of multiple mediators [e.g., kallikrein, plasmin] results in the attenuation of inflammatory responses, fibrinolysis, and thrombin generation. Aprotinin inhibits pro-inflammatory cytokine release and maintains glycoprotein homeostasis. In platelets, aprotinin reduces glycoprotein loss (e.g., GpIb, GpIIb/IIIa), while in granulocytes it prevents the expression of pro-inflammatory adhesive glycoproteins (e.g., CD11b). The effects of aprotinin use in CPB involves a reduction in inflammatory response which translates into a decreased need for allogeneic blood transfusions, reduced bleeding, and decreased mediastinal re-exploration for bleeding.

# Predicted_LogP_Hydrophobicity:
Not Available

# Predicted_LogS:
Not Available

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB06692

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/trasylol-drug.htm

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
liquid

# Structure:
0

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
BPTI
Bayer A 128
Iniprol
Trazinin
bovine pancreatic trypsin inhibitor

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2010-09-29 14:35:04 -0600

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Aprotinin

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Secreted protein
extracellular space

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
15277296	Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth. 2004 Dec;93(6):842-58. Epub 2004 Jul 26.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
PRSS1

# Drug_Target_1_GenBank_ID_Gene:
M22612

# Drug_Target_1_GenBank_ID_Protein:
521216

# Drug_Target_1_GeneCard_ID:
PRSS1

# Drug_Target_1_Gene_Name:
PRSS1

# Drug_Target_1_Gene_Sequence:
>744 bp
ATGAATCCACTCCTGATCCTTACCTTTGTGGCAGCTGCTCTTGCTGCCCCCTTTGATGAT
GATGACAAGATCGTTGGGGGCTACAACTGTGAGGAGAATTCTGTCCCCTACCAGGTGTCC
CTGAATTCTGGCTACCACTTCTGTGGTGGCTCCCTCATCAACGAACAGTGGGTGGTATCA
GCAGGCCACTGCTACAAGTCCCGCATCCAGGTGAGACTGGGAGAGCACAACATCGAAGTC
CTGGAGGGGAATGAGCAGTTCATCAATGCAGCCAAGATCATCCGCCACCCCCAATACGAC
AGGAAGACTCTGAACAATGACATCATGTTAATCAAGCTCTCCTCACGTGCAGTAATCAAC
GCCCGCGTGTCCACCATCTCTCTGCCCACCGCCCCTCCAGCCACTGGCACGAAGTGCCTC
ATCTCTGGCTGGGGCAACACTGCGAGCTCTGGCGCCGACTACCCAGACGAGCTGCAGTGC
CTGGATGCTCCTGTGCTGAGCCAGGCTAAGTGTGAAGCCTCCTACCCTGGAAAGATTACC
AGCAACATGTTCTGTGTGGGCTTCCTTGAGGGAGGCAAGGATTCATGTCAGGGTGATTCT
GGTGGCCCTGTGGTCTGCAATGGACAGCTCCAAGGAGTTGTCTCCTGGGGTGATGGCTGT
GCCCAGAAGAACAAGCCTGGAGTCTACACCAAGGTCTACAACTACGTGAAATGGATTAAG
AACACCATAGCTGCCAATAGCTAA

# Drug_Target_1_General_Function:
Involved in protease activity

# Drug_Target_1_General_References:
10204851	Ferec C, Raguenes O, Salomon R, Roche C, Bernard JP, Guillot M, Quere I, Faure C, Mercier B, Audrezet MP, Guillausseau PJ, Dupont C, Munnich A, Bignon JD, Le Bodic L: Mutations in the cationic trypsinogen gene and evidence for genetic heterogeneity in hereditary pancreatitis. J Med Genet. 1999 Mar;36(3):228-32.
10381903	Witt H, Luck W, Becker M: A signal peptide cleavage site mutation in the cationic trypsinogen gene is strongly associated with chronic pancreatitis. Gastroenterology. 1999 Jul;117(1):7-10.
10930381	Teich N, Ockenga J, Hoffmeister A, Manns M, Mossner J, Keim V: Chronic pancreatitis associated with an activation peptide mutation that facilitates trypsin activation. Gastroenterology. 2000 Aug;119(2):461-5.
11788572	Pfutzer R, Myers E, Applebaum-Shapiro S, Finch R, Ellis I, Neoptolemos J, Kant JA, Whitcomb DC: Novel cationic trypsinogen (PRSS1) N29T and R122C mutations cause autosomal dominant hereditary pancreatitis. Gut. 2002 Feb;50(2):271-2.
2598466	Kimland M, Russick C, Marks WH, Borgstrom A: Immunoreactive anionic and cationic trypsin in human serum. Clin Chim Acta. 1989 Sep 15;184(1):31-46.
3011602	Emi M, Nakamura Y, Ogawa M, Yamamoto T, Nishide T, Mori T, Matsubara K: Cloning, characterization and nucleotide sequences of two cDNAs encoding human pancreatic trypsinogens. Gene. 1986;41(2-3):305-10.
8683601	Gaboriaud C, Serre L, Guy-Crotte O, Forest E, Fontecilla-Camps JC: Crystal structure of human trypsin 1: unexpected phosphorylation of Tyr151. J Mol Biol. 1996 Jun 28;259(5):995-1010.
8841182	Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, Martin SP, Gates LK Jr, Amann ST, Toskes PP, Liddle R, McGrath K, Uomo G, Post JC, Ehrlich GD: Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996 Oct;14(2):141-5.
9322498	Gorry MC, Gabbaizedeh D, Furey W, Gates LK Jr, Preston RA, Aston CE, Zhang Y, Ulrich C, Ehrlich GD, Whitcomb DC: Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology. 1997 Oct;113(4):1063-8.
9633818	Teich N, Mossner J, Keim V: Mutations of the cationic trypsinogen in hereditary pancreatitis. Hum Mutat. 1998;12(1):39-43.

# Drug_Target_1_HGNC_ID:
HGNC:9475

# Drug_Target_1_HPRD_ID:
02039

# Drug_Target_1_ID:
3176

# Drug_Target_1_Locus:
7q32-qter|7q34

# Drug_Target_1_Molecular_Weight:
26558

# Drug_Target_1_Name:
Trypsin-1

# Drug_Target_1_Number_of_Residues:
247

# Drug_Target_1_PDB_ID:
1TRN

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00089	Trypsin

# Drug_Target_1_Protein_Sequence:
>Trypsin-1 precursor
MNPLLILTFVAAALAAPFDDDDKIVGGYNCEENSVPYQVSLNSGYHFCGGSLINEQWVVS
AGHCYKSRIQVRLGEHNIEVLEGNEQFINAAKIIRHPQYDRKTLNNDIMLIKLSSRAVIN
ARVSTISLPTAPPATGTKCLISGWGNTASSGADYPDELQCLDAPVLSQAKCEASYPGKIT
SNMFCVGFLEGGKDSCQGDSGGPVVCNGQLQGVVSWGDGCAQKNKPGVYTKVYNYVKWIK
NTIAANS

# Drug_Target_1_Reaction:
Preferential cleavage: Arg!, Lys! INHIBITOR Tos-Lys-CH2Cl; Tos-Arg-CH2Cl

# Drug_Target_1_Signals:
1-15

# Drug_Target_1_Specific_Function:
Preferential cleavage:Arg-|-Xaa, Lys-|-Xaa

# Drug_Target_1_SwissProt_ID:
P07477

# Drug_Target_1_SwissProt_Name:
TRY1_HUMAN

# Drug_Target_1_Synonyms:
Cationic trypsinogen
EC 3.4.21.4
Serine protease 1
Trypsin I
Trypsin-1 precursor

# Drug_Target_1_Theoretical_pI:
6.48

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Secreted, extracellular space

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
15277296	Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth. 2004 Dec;93(6):842-58. Epub 2004 Jul 26.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
CTRB1

# Drug_Target_2_GenBank_ID_Gene:
BC005385

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
CTRB1

# Drug_Target_2_Gene_Name:
CTRB1

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
2917002	Tomita N, Izumoto Y, Horii A, Doi S, Yokouchi H, Ogawa M, Mori T, Matsubara K: Molecular cloning and nucleotide sequence of human pancreatic prechymotrypsinogen cDNA. Biochem Biophys Res Commun. 1989 Jan 31;158(2):569-75.

# Drug_Target_2_HGNC_ID:
HGNC:2521

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
6011

# Drug_Target_2_Locus:
16q23-q24.1

# Drug_Target_2_Molecular_Weight:
27870

# Drug_Target_2_Name:
Chymotrypsinogen B

# Drug_Target_2_Number_of_Residues:
263

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00089	Trypsin

# Drug_Target_2_Protein_Sequence:
>Chymotrypsinogen B
MAFLWLLSCWALLGTTFGCGVPAIHPVLSGLSRIVNGEDAVPGSWPWQVSLQDKTGFHFC
GGSLISEDWVVTAAHCGVRTSDVVVAGEFDQGSDEENIQVLKIAKVFKNPKFSILTVNND
ITLLKLATPARFSQTVSAVCLPSADDDFPAGTLCATTGWGKTKYNANKTPDKLQQAALPL
LSNAECKKSWGRRITDVMICAGASGVSSCMGDSGGPLVCQKDGAWTLVGIVSWGSDTCST
SSPGVYARVTKLIPWVQKILAAN

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-18

# Drug_Target_2_Specific_Function:
Preferential cleavage:Tyr-|-Xaa, Trp-|-Xaa, Phe-|-Xaa, Leu-|-Xaa

# Drug_Target_2_SwissProt_ID:
P17538

# Drug_Target_2_SwissProt_Name:
CTRB1_HUMAN

# Drug_Target_2_Synonyms:
Contains: RecName: Chymotrypsin B chain A
Contains: RecName: Chymotrypsin B chain B
Contains: RecName: Chymotrypsin B chain C

# Drug_Target_2_Theoretical_pI:
7.17

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Secreted protein

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
15277296	Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth. 2004 Dec;93(6):842-58. Epub 2004 Jul 26.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
PLG

# Drug_Target_3_GenBank_ID_Gene:
X05199

# Drug_Target_3_GenBank_ID_Protein:
387026

# Drug_Target_3_GeneCard_ID:
PLG

# Drug_Target_3_Gene_Name:
PLG

# Drug_Target_3_Gene_Sequence:
>2433 bp
ATGGAACATAAGGAAGTGGTTCTTCTACTTCTTTTATTTCTGAAATCAGGTCAAGGAGAG
CCTCTGGATGACTATGTGAATACCCAGGGGGCTTCACTGTTCAGTGTCACTAAGAAGCAG
CTGGGAGCAGGAAGTATAGAAGAATGTGCAGCAAAATGTGAGGAGGACGAAGAATTCACC
TGCAGGGCATTCCAATATCACAGTAAAGAGCAACAATGTGTGATAATGGCTGAAAACAGG
AAGTCCTCCATAATCATTAGGATGAGAGATGTAGTTTTATTTGAAAAGAAAGTGTATCTC
TCAGAGTGCAAGACTGGGAATGGAAAGAATTACAGAGGGACGATGTCCAAAACAAAAAAT
GGCATCACCTGTCAAAAATGGAGTTCCACTTCTCCCCACAGACCTAGATTCTCACCTGCT
ACACACCCCTCAGAGGGACTGGAGGAGAACTACTGCAGGAATCCAGACAACGATCCGCAG
GGGCCCTGGTGCTATACTACTGATCCAGAAAAGAGATATGACTACTGCGACATTCTTGAG
TGTGAAGAGGAATGTATGCATTGCAGTGGAGAAAACTATGACGGCAAAATTTCCAAGACC
ATGTCTGGACTGGAATGCCAGGCCTGGGACTCTCAGAGCCCACACGCTCATGGATACATT
CCTTCCAAATTTCCAAACAAGAACCTGAAGAAGAATTACTGTCGTAACCCCGATAGGGAG
CTGCGGCCTTGGTGTTTCACCACCGACCCCAACAAGCGCTGGGAACTTTGCGACATCCCC
CGCTGCACAACACCTCCACCATCTTCTGGTCCCACCTACCAGTGTCTGAAGGGAACAGGT
GAAAACTATCGCGGGAATGTGGCTGTTACCGTGTCCGGGCACACCTGTCAGCACTGGAGT
GCACAGACCCCTCACACACATAACAGGACACCAGAAAACTTTCCCTGCAAAAATTTGGAT
GAAAACTACTGCCGCAATCCTGACGGAAAAAGGGCCCCATGGTGCCATACAACCAACAGC
CAAGTGCGGTGGGAGTACTGTAAGATACCGTCCTGTGACTCCTCCCCAGTATCCACGGAA
CAATTGGCTCCCACAGCACCACCTGAGCTAACCCCTGTGGTCCAGGACTGCTACCATGGT
GATGGACAGAGCTACCGAGGCACATCCTCCACCACCACCACAGGAAAGAAGTGTCAGTCT
TGGTCATCTATGACACCACACCGGCACCAGAAGACCCCAGAAAACTACCCAAATGCTGGC
CTGACAATGAACTACTGCAGGAATCCAGATGCCGATAAAGGCCCCTGGTGTTTTACCACA
GACCCCAGCGTCAGGTGGGAGTACTGCAACCTGAAAAAATGCTCAGGAACAGAAGCGAGT
GTTGTAGCACCTCCGCCTGTTGTCCTGCTTCCAAATGTAGAGACTCCTTCCGAAGAAGAC
TGTATGTTTGGGAATGGGAAAGGATACCGAGGCAAGAGGGCGACCACTGTTACTGGGACG
CCATGCCAGGACTGGGCTGCCCAGGAGCCCCATAGACACAGCATTTTCACTCCAGAGACA
AATCCACGGGCGGGTCTGGAAAAAAATTACTGCCGTAACCCTGATGGTGATGTAGGTGGT
CCCTGGTGCTACACGACAAATCCAAGAAAACTTTACGACTACTGTGATGTCCCTCAGTGT
GCGGCCCCTTCATTTGATTGTGGGAAGCCTCAAGTGGAGCCGAAGAAATGTCCTGGAAGG
GTTGTAGGGGGGTGTGTGGCCCACCCACATTCCTGGCCCTGGCAAGTCAGTCTTAGAACA
AGGTTTGGAATGCACTTCTGTGGAGGCACCTTGATATCCCCAGAGTGGGTGTTGACTGCT
GCCCACTGCTTGGAGAAGTCCCCAAGGCCTTCATCCTACAAGGTCATCCTGGGTGCACAC
CAAGAAGTGAATCTCGAACCGCATGTTCAGGAAATAGAAGTGTCTAGGCTGTTCTTGGAG
CCCACACGAAAAGATATTGCCTTGCTAAAGCTAAGCAGTCCTGCCGTCATCACTGACAAA
GTAATCCCAGCTTGTCTGCCATCCCCAAATTATGTGGTCGCTGACCGGACCGAATGTTTC
ATCACTGGCTGGGGAGAAACCCAAGGTACTTTTGGAGCTGGCCTTCTCAAGGAAGCCCAG
CTCCCTGTGATTGAGAATAAAGTGTGCAATCGCTATGAGTTTCTGAATGGAAGAGTCCAA
TCCACCGAACTCTGTGCTGGGCATTTGGCCGGAGGCACTGACAGTTGCCAGGGTGACAGT
GGAGGGCCTCTGGTTTGCTTCGAGAAGGACAAATACATTTTACAAGGAGTCACTTCTTGG
GGTCTTGGCTGTGCACGCCCCAATAAGCCTGGTGTCTATGTTCGTGTTTCAAGGTTTGTT
ACTTGGATTGAGGGAGTGATGAGAAATAATTAA

# Drug_Target_3_General_Function:
Involved in plasmin activity

# Drug_Target_3_General_References:
10233898	Schuster V, Seidenspinner S, Zeitler P, Escher C, Pleyer U, Bernauer W, Stiehm ER, Isenberg S, Seregard S, Olsson T, Mingers AM, Schambeck C, Kreth HW: Compound-heterozygous mutations in the plasminogen gene predispose to the development of ligneous conjunctivitis. Blood. 1999 May 15;93(10):3457-66.
122932	Wiman B, Wallen P: Structural relationship between "glutamic acid" and "lysine" forms of human plasminogen and their interaction with the NH2-terminal activation peptide as studied by affinity chromatography. Eur J Biochem. 1975 Jan 15;50(3):489-94.
126863	Wiman B, Wallen P: Amino-acid sequence of the cyanogen-bromide fragment from human plasminogen that forms the linkage between the plasmin chains. Eur J Biochem. 1975 Oct 15;58(2):539-47.
142009	Wiman B: Primary structure of the B-chain of human plasmin. Eur J Biochem. 1977 Jun 1;76(1):129-37.
1427790	Kikuchi S, Yamanouchi Y, Li L, Kobayashi K, Ijima H, Miyazaki R, Tsuchiya S, Hamaguchi H: Plasminogen with type-I mutation is polymorphic in the Japanese population. Hum Genet. 1992 Sep-Oct;90(1-2):7-11.
1657148	Mulichak AM, Tulinsky A, Ravichandran KG: Crystal and molecular structure of human plasminogen kringle 4 refined at 1.9-A resolution. Biochemistry. 1991 Oct 29;30(43):10576-88.
1657149	Wu TP, Padmanabhan K, Tulinsky A, Mulichak AM: The refined structure of the epsilon-aminocaproic acid complex of human plasminogen kringle 4. Biochemistry. 1991 Oct 29;30(43):10589-94.
1986355	Ichinose A, Espling ES, Takamatsu J, Saito H, Shinmyozu K, Maruyama I, Petersen TE, Davie EW: Two types of abnormal genes for plasminogen in families with a predisposition for thrombosis. Proc Natl Acad Sci U S A. 1991 Jan 1;88(1):115-9.
2157850	Atkinson RA, Williams RJ: Solution structure of the kringle 4 domain from human plasminogen by 1H nuclear magnetic resonance spectroscopy and distance geometry. J Mol Biol. 1990 Apr 5;212(3):541-52.
2318848	Petersen TE, Martzen MR, Ichinose A, Davie EW: Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J Biol Chem. 1990 Apr 15;265(11):6104-11.
3030813	Forsgren M, Raden B, Israelsson M, Larsson K, Heden LO: Molecular cloning and characterization of a full-length cDNA clone for human plasminogen. FEBS Lett. 1987 Mar 23;213(2):254-60.
3356193	Marti T, Schaller J, Rickli EE, Schmid K, Kamerling JP, Gerwig GJ, van Halbeek H, Vliegenthart JF: The N- and O-linked carbohydrate chains of human, bovine and porcine plasminogen. Species specificity in relation to sialylation and fucosylation patterns. Eur J Biochem. 1988 Apr 5;173(1):57-63.
4240117	Groskopf WR, Summaria L, Robbins KC: Studies on the active center of human plasmin. Partial amino acid sequence of a peptide containing the active center serine residue. J Biol Chem. 1969 Jul 10;244(13):3590-7.
4694729	Robbins KC, Bernabe P, Arzadon L, Summaria L: The primary structure of human plasminogen. II. The histidine loop of human plasmin: light (B) chain active center histidine sequence. J Biol Chem. 1973 Mar 10;248(5):1631-3.
6094526	Vali Z, Patthy L: The fibrin-binding site of human plasminogen. Arginines 32 and 34 are essential for fibrin affinity of the kringle 1 domain. J Biol Chem. 1984 Nov 25;259(22):13690-4.
6148961	Malinowski DP, Sadler JE, Davie EW: Characterization of a complementary deoxyribonucleic acid coding for human and bovine plasminogen. Biochemistry. 1984 Aug 28;23(18):4243-50.
6216475	Miyata T, Iwanaga S, Sakata Y, Aoki N: Plasminogen Tochigi: inactive plasmin resulting from replacement of alanine-600 by threonine in the active site. Proc Natl Acad Sci U S A. 1982 Oct;79(20):6132-6.
6238949	Miyata T, Iwanaga S, Sakata Y, Aoki N, Takamatsu J, Kamiya T: Plasminogens Tochigi II and Nagoya: two additional molecular defects with Ala-600----Thr replacement found in plasmin light chain variants. J Biochem (Tokyo). 1984 Aug;96(2):277-87.
6919539	Trexler M, Vali Z, Patthy L: Structure of the omega-aminocarboxylic acid-binding sites of human plasminogen. Arginine 70 and aspartic acid 56 are essential for binding of ligand by kringle 4. J Biol Chem. 1982 Jul 10;257(13):7401-6.
7525077	O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994 Oct 21;79(2):315-28.
8181475	Rejante MR, Llinas M: 1H-NMR assignments and secondary structure of human plasminogen kringle 1. Eur J Biochem. 1994 May 1;221(3):927-37.
8181476	Rejante MR, Llinas M: Solution structure of the epsilon-aminohexanoic acid complex of human plasminogen kringle 1. Eur J Biochem. 1994 May 1;221(3):939-49.
8392398	Azuma H, Uno Y, Shigekiyo T, Saito S: Congenital plasminogen deficiency caused by a Ser572 to Pro mutation. Blood. 1993 Jul 15;82(2):475-80.
8611560	Mathews II, Vanderhoff-Hanaver P, Castellino FJ, Tulinsky A: Crystal structures of the recombinant kringle 1 domain of human plasminogen in complexes with the ligands epsilon-aminocaproic acid and trans-4-(aminomethyl)cyclohexane-1-carboxylic Acid. Biochemistry. 1996 Feb 27;35(8):2567-76.
8652577	Sohndel S, Hu CK, Marti D, Affolter M, Schaller J, Llinas M, Rickli EE: Recombinant gene expression and 1H NMR characteristics of the kringle (2 + 3) supermodule: spectroscopic/functional individuality of plasminogen kringle domains. Biochemistry. 1996 Feb 20;35(7):2357-64.
9054441	Pirie-Shepherd SR, Stevens RD, Andon NL, Enghild JJ, Pizzo SV: Evidence for a novel O-linked sialylated trisaccharide on Ser-248 of human plasminogen 2. J Biol Chem. 1997 Mar 14;272(11):7408-11.
9102221	Sim BK, O'Reilly MS, Liang H, Fortier AH, He W, Madsen JW, Lapcevich R, Nacy CA: A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res. 1997 Apr 1;57(7):1329-34.
9201958	Wang H, Prorok M, Bretthauer RK, Castellino FJ: Serine-578 is a major phosphorylation locus in human plasma plasminogen. Biochemistry. 1997 Jul 1;36(26):8100-6.
9242524	Schuster V, Mingers AM, Seidenspinner S, Nussgens Z, Pukrop T, Kreth HW: Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis. Blood. 1997 Aug 1;90(3):958-66.
9521645	Chang Y, Mochalkin I, McCance SG, Cheng B, Tulinsky A, Castellino FJ: Structure and ligand binding determinants of the recombinant kringle 5 domain of human plasminogen. Biochemistry. 1998 Mar 10;37(10):3258-71.
9858247	Higuchi Y, Furihata K, Ueno I, Ishikawa S, Okumura N, Tozuka M, Sakurai N: Plasminogen Kanagawa-I, a novel missense mutation, is caused by the amino acid substitution G732R. Br J Haematol. 1998 Dec;103(3):867-70.

# Drug_Target_3_HGNC_ID:
HGNC:9071

# Drug_Target_3_HPRD_ID:
01417

# Drug_Target_3_ID:
234

# Drug_Target_3_Locus:
6q26

# Drug_Target_3_Molecular_Weight:
90569

# Drug_Target_3_Name:
Plasminogen

# Drug_Target_3_Number_of_Residues:
810

# Drug_Target_3_PDB_ID:
1KI0

# Drug_Target_3_Pathway:
Acenocoumarol Pathway	SMP00269
Alteplase Pathway	SMP00280
Aminocaproic Acid Pathway	SMP00286
Anistreplase Pathway	SMP00281
Aprotinin Pathway	SMP00288
Ardeparin Pathway	SMP00275
Argatroban Pathway	SMP00276
Bivalirudin Pathway	SMP00277
Dicumarol Pathway	SMP00270
Enoxaparin Pathway	SMP00272
Fondaparinux Pathway	SMP00273
Heparin Pathway	SMP00274
Lepirudin Pathway	SMP00278
Phenprocoumon Pathway	SMP00271
Reteplase Pathway	SMP00285
Streptokinase Pathway	SMP00282
Tenecteplase Pathway	SMP00283
Tranexamic Acid Pathway	SMP00287
Urokinase Pathway	SMP00284
Warfarin Pathway	SMP00268
Ximelagatran Pathway	SMP00279

# Drug_Target_3_Pfam_Domain_Function:
PF00024	PAN_1
PF00051	Kringle
PF00089	Trypsin

# Drug_Target_3_Protein_Sequence:
>Plasminogen precursor
MEHKEVVLLLLLFLKSGQGEPLDDYVNTQGASLFSVTKKQLGAGSIEECAAKCEEDEEFT
CRAFQYHSKEQQCVIMAENRKSSIIIRMRDVVLFEKKVYLSECKTGNGKNYRGTMSKTKN
GITCQKWSSTSPHRPRFSPATHPSEGLEENYCRNPDNDPQGPWCYTTDPEKRYDYCDILE
CEEECMHCSGENYDGKISKTMSGLECQAWDSQSPHAHGYIPSKFPNKNLKKNYCRNPDRE
LRPWCFTTDPNKRWELCDIPRCTTPPPSSGPTYQCLKGTGENYRGNVAVTVSGHTCQHWS
AQTPHTHNRTPENFPCKNLDENYCRNPDGKRAPWCHTTNSQVRWEYCKIPSCDSSPVSTE
QLAPTAPPELTPVVQDCYHGDGQSYRGTSSTTTTGKKCQSWSSMTPHRHQKTPENYPNAG
LTMNYCRNPDADKGPWCFTTDPSVRWEYCNLKKCSGTEASVVAPPPVVLLPDVETPSEED
CMFGNGKGYRGKRATTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGG
PWCYTTNPRKLYDYCDVPQCAAPSFDCGKPQVEPKKCPGRVVGGCVAHPHSWPWQVSLRT
RFGMHFCGGTLISPEWVLTAAHCLEKSPRPSSYKVILGAHQEVNLEPHVQEIEVSRLFLE
PTRKDIALLKLSSPAVITDKVIPACLPSPNYVVADRTECFITGWGETQGTFGAGLLKEAQ
LPVIENKVCNRYEFLNGRVQSTELCAGHLAGGTDSCQGDSGGPLVCFEKDKYILQGVTSW
GLGCARPNKPGVYVRVSRFVTWIEGVMRNN

# Drug_Target_3_Reaction:
Preferential cleavage: Lys! > Arg!; higher selectivity than trypsin. Converts fibrin into soluble products

# Drug_Target_3_Signals:
1-19

# Drug_Target_3_Specific_Function:
Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo

# Drug_Target_3_SwissProt_ID:
P00747

# Drug_Target_3_SwissProt_Name:
PLMN_HUMAN

# Drug_Target_3_Synonyms:
EC 3.4.21.7
Plasminogen precursor

# Drug_Target_3_Theoretical_pI:
7.25

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Cytoplasmic

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
15277296	Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth. 2004 Dec;93(6):842-58. Epub 2004 Jul 26.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
KLK1

# Drug_Target_4_GenBank_ID_Gene:
M25629

# Drug_Target_4_GenBank_ID_Protein:
186653

# Drug_Target_4_GeneCard_ID:
KLK1

# Drug_Target_4_Gene_Name:
KLK1

# Drug_Target_4_Gene_Sequence:
>789 bp
ATGTGGTTCCTGGTTCTGTGCCTCGCCCTGTCCCTGGGGGGGACTGGTGCTGCGCCCCCG
ATTCAGTCCCGGATTGTGGGAGGCTGGGAGTGTGAGCAGCATTCCCAGCCCTGGCAGGCG
GCTCTGTACCATTTCAGCACTTTCCAGTGTGGGGGCATCCTGGTGCACCGCCAGTGGGTG
CTCACAGCTGCTCATTGCATCAGCGACAATTACCAGCTCTGGCTGGGTCGCCACAACTTG
TTTGACGACGAAAACACAGCCCAGTTTGTTCATGTCAGTGAGAGCTTCCCACACCCTGGC
TTCAACATGAGCCTCCTGGAGAACCACACCCGCCAAGCAGACGAGGACTACAGCCACGAC
CTCATGCTGCTCCGCCTGACAGAGCCTGCTGATACCATCACAGACGCTGTGAAGGTCGTG
GAGTTGCCCACCCAGGAACCCGAAGTGGGGAGCACCTGTTTGGCTTCCGGCTGGGGCAGC
ATCGAACCAGAGAATTTCTCATTTCCAGATGATCTCCAGTGTGTGGACCTCAAAATCCTG
CCTAATGATGAGTGCGAAAAAGCCCACGTCCAGAAGGTGACAGACTTCATGCTGTGTGTC
GGACACCTGGAAGGTGGCAAAGACACCTGTGTGGGTGATTCAGGGGGCCCGCTGATGTGT
GATGGTGTGCTCCAAGGTGTCACATCATGGGGCTACGTCCCTTGTGGCACCCCCAATAAG
CCTTCTGTCGCCGTCAGAGTGCTGTCTTATGTGAAGTGGATCGAGGACACCATAGCGGAG
AACTCCTGA

# Drug_Target_4_General_Function:
Involved in protease activity

# Drug_Target_4_General_References:
2666327	Lu HS, Lin FK, Chao L, Chao J: Human urinary kallikrein. Complete amino acid sequence and sites of glycosylation. Int J Pept Protein Res. 1989 Apr;33(4):237-49.
2686621	Angermann A, Bergmann C, Appelhans H: Cloning and expression of human salivary-gland kallikrein in Escherichia coli. Biochem J. 1989 Sep 15;262(3):787-93.
2898948	Evans BA, Yun ZX, Close JA, Tregear GW, Kitamura N, Nakanishi S, Callen DF, Baker E, Hyland VJ, Sutherland GR, et al.: Structure and chromosomal localization of the human renal kallikrein gene. Biochemistry. 1988 May 3;27(9):3124-9.
3004571	Fukushima D, Kitamura N, Nakanishi S: Nucleotide sequence of cloned cDNA for human pancreatic kallikrein. Biochemistry. 1985 Dec 31;24(27):8037-43.
3163150	Kellermann J, Lottspeich F, Geiger R, Deutzmann R: Human urinary kallikrein--amino acid sequence and carbohydrate attachment sites. Protein Seq Data Anal. 1988 Feb;1(3):177-82.
3635530	Takahashi S, Irie A, Katayama Y, Ito K, Miyake Y: N-terminal amino acid sequence of human urinary prokallikrein. J Biochem (Tokyo). 1986 Mar;99(3):989-92.
3853975	Baker AR, Shine J: Human kidney kallikrein: cDNA cloning and sequence analysis. DNA. 1985 Dec;4(6):445-50.
393608	Lottspeich F, Geiger R, Henschen A, Kutzbach C: N-Terminal amino acid sequence of human urinary kallikrein homology with other serine proteases. Hoppe Seylers Z Physiol Chem. 1979 Dec;360(12):1947-50.

# Drug_Target_4_HGNC_ID:
HGNC:6357

# Drug_Target_4_HPRD_ID:
01003

# Drug_Target_4_ID:
1812

# Drug_Target_4_Locus:
19q13.3

# Drug_Target_4_Molecular_Weight:
28890

# Drug_Target_4_Name:
Kallikrein-1

# Drug_Target_4_Number_of_Residues:
262

# Drug_Target_4_PDB_ID:
1SPJ

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00089	Trypsin

# Drug_Target_4_Protein_Sequence:
>Kallikrein-1 precursor
MWFLVLCLALSLGGTGAAPPIQSRIVGGWECEQHSQPWQAALYHFSTFQCGGILVHRQWV
LTAAHCISDNYQLWLGRHNLFDDENTAQFVHVSESFPHPGFNMSLLENHTRQADEDYSHD
LMLLRLTEPADTITDAVKVVELPTQEPEVGSTCLASGWGSIEPENFSFPDDLQCVDLKIL
PNDECEKAHVQKVTDFMLCVGHLEGGKDTCVGDSGGPLMCDGVLQGVTSWGYVPCGTPNK
PSVAVRVLSYVKWIEDTIAENS

# Drug_Target_4_Reaction:
Preferential cleavage of Arg! bonds in small molecule substrates. Highly selective action to release kallidin (lysyl-bradykinin) from kininogen involves hydrolysis of Met! or Leu!. The rat enzyme is unusual in liberating bradykinin directly from autologous kininogens by cleavage at two Arg! bonds [5]

# Drug_Target_4_Signals:
1-18

# Drug_Target_4_Specific_Function:
Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin

# Drug_Target_4_SwissProt_ID:
P06870

# Drug_Target_4_SwissProt_Name:
KLK1_HUMAN

# Drug_Target_4_Synonyms:
EC 3.4.21.35
Kallikrein-1 precursor
Kidney/pancreas/salivary gland kallikrein
Tissue kallikrein

# Drug_Target_4_Theoretical_pI:
4.39

# Drug_Target_4_Transmembrane_Regions:
None

#END_DRUGCARD DB06692
